It also outlines criteria for assessing their efficacy both in vitro and in vivo
doi: 10.3389/fendo.2026.1788698 Received 15 January 2026 Revised 30 January 2026 Accepted 13 February 2026 Published 03 March 2026 Volume 17 - 2026 Edited by Ploutarchos Tzoulis, University College London, United Kingdom Reviewed by Lai San Tham, Eli Lilly, United States Updates Copyright 2026 Alhazmi and le Roux
Scientists are studying their effects on fatty liver disease (NAFLD and NASH), polycystic ovary syndrome (PCOS), addiction and impulse-control disorders, neurodegenerative diseases, and inflammatory bowel disease
Yet the consequences are unknown Bioavailability: there are four specific metabolic steps necessary to convert cyanocobalamin into one of the coenzyme forms, which is a clear metabolic disadvantage (3) Utilisation problems: certain hereditary diseases, as well as metabolic disorders, prevent the conversion of cyanocoalamin into the active B12 forms (4) Steals methyl groups: cyanocobalamin requires a methyl group to convert into methylcobalamin, which it takes from the important amino acid S-adenosylmethionine (SAM)
For patients considering GLP-1 weight loss, medical weight loss, semaglutide, or tirzepatide, side-effect management should be part of the treatment plan from the beginning
Some researchers explore hexarelins promising effect on myocardial stress response pathways
.webp)
